PMID- 28353016
OWN - NLM
STAT- MEDLINE
DCOM- 20171019
LR  - 20220408
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 12
IP  - 3
DP  - 2017 Jun
TI  - New Therapeutic Strategies in Acute Lymphocytic Leukemia.
PG  - 197-206
LID - 10.1007/s11899-017-0380-3 [doi]
AB  - Most drugs used in standard regimens for acute lymphoblastic leukemia (ALL) were 
      developed more than 30 years ago. Since that time, several new drugs have been 
      developed and incorporated into ALL treatment. In spite of this, novel 
      therapeutic approaches are still needed to improve outcomes for high-risk or 
      relapsed ALL. This manuscript discusses newer treatment strategies, including 
      purine nucleoside analogs, monoclonal antibodies, antibody drug conjugates, 
      mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, histone 
      deacetylase (HDAC) inhibitors, hypomethylating agents, spleen tyrosine kinase 
      inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, Janus kinase-signal 
      transducer and activator of transcription (JAK-STAT) inhibitors, anti-programmed 
      cell death protein (anti-PD-1) antibodies, mitogen-activated protein kinase (MEK) 
      inhibitors, CXCR4 antagonists, poly (ADP-ribose) polymerase (PARP) inhibitors, 
      and FMS-like tyrosine kinase 3 (FLT3) inhibitors. Additionally, this manuscript 
      discusses the impact of diagnostic approaches on management of ALL. Specifically, 
      minimal residual disease is increasingly felt to be important and will likely 
      dramatically impact the care of ALL patients in the near future.
FAU - Man, Louise M
AU  - Man LM
AD  - Division of Hematology/Oncology, University of Virginia Health System, 1300 
      Jefferson Park Avenue, Room 6023, PO Box 800716, Charlottesville, VA, 22903, USA.
FAU - Morris, Amy L
AU  - Morris AL
AD  - Department of Pharmacy Services, University of Virginia Medical Center, 
      Charlottesville, VA, 22903, USA.
FAU - Keng, Michael
AU  - Keng M
AD  - Division of Hematology/Oncology, University of Virginia Health System, 1300 
      Jefferson Park Avenue, Room 6023, PO Box 800716, Charlottesville, VA, 22903, USA. 
      MK2PV@hscmail.mcc.virginia.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Immunoconjugates)
RN  - 0 (Proteasome Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Biomarkers, Tumor
MH  - Clinical Trials as Topic
MH  - Epigenesis, Genetic/drug effects
MH  - Histone Deacetylase Inhibitors/pharmacology/therapeutic use
MH  - Humans
MH  - Immunoconjugates/pharmacology/therapeutic use
MH  - *Molecular Targeted Therapy
MH  - Neoplasm, Residual/pathology
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug 
      therapy/etiology/metabolism/pathology
MH  - Proteasome Inhibitors/pharmacology/therapeutic use
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Signal Transduction/drug effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia
OT  - Acute lymphocytic leukemias
OT  - Antibody drug conjugates
OT  - Monoclonal antibodies
OT  - Purine nucleoside analogs
OT  - Therapeutic approaches
EDAT- 2017/03/30 06:00
MHDA- 2017/10/20 06:00
CRDT- 2017/03/30 06:00
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
PHST- 2017/03/30 06:00 [entrez]
AID - 10.1007/s11899-017-0380-3 [pii]
AID - 10.1007/s11899-017-0380-3 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2017 Jun;12(3):197-206. doi: 10.1007/s11899-017-0380-3.